- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04895202
Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study (SWISSMASIA)
Swiss Study of the Impact of Mayzent (Siponimod) on Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Basel, Switzerland, 4031
- Novartis Investigative Site
-
Bern, Switzerland, 3010
- Novartis Investigative Site
-
Lugano, Switzerland, 6900
- Novartis Investigative Site
-
Winterthur, Switzerland, 8400
- Novartis Investigative Site
-
-
ZG
-
Zug, ZG, Switzerland, 6300
- Novartis Investigative Site
-
-
ZH
-
Zurich, ZH, Switzerland, 8006
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed informed consent
- Adult patients with a documented diagnosis of SPMS with inflammatory disease activity who are going to be treated with Siponimod under routine medical care and in accordance with the Swiss label
- Patient willing and able to complete the questionnaires
Exclusion Criteria:
- Patients treated outside of the approved Swiss label for Siponimod
- Prior treatment or already ongoing treatment with Siponimod
- Use of investigational drugs during the study, OR within 3 months before enrollment, OR within 5 half-lives of investigational drug before enrollment, OR until the expected pharmacodynamic effect has returned to baseline, whichever is longer
- Subjects who are not able to provide consent due to incapable judgement
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Siponimod
Patients administered Siponimod as per Swiss label
|
Prospective observational cohort study.
There is no treatment allocation.
Patients administered siponimod as by swiss label, that have started before inclusion of the patient into the study will be enrolled.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of expanded disability status scale (EDSS)
Time Frame: Baseline, month 36
|
The EDSS score is a widely used tool for determining the degree of disability in MS at any point in time.
The EDSS value is generated based on overall impression and individual scores of the following functional systems: cognition, mood, fatigue, vision, brain stem, upper extremities, lower extremities, bladder and bowel function, sexuality.
This results in a scale from 0 (healthy) to 10 (death from MS)
|
Baseline, month 36
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with six month confirmed disability progression (CDP) by expanded disability status scale (EDSS)
Time Frame: month 36
|
Disability progression based on the EDSS score is defined as a 1 point increase from baseline in patients with a baseline score of ≤ 5, or a 0.5 point increase in patients with a baseline score of ≥5.5.
As part of a secondary endpoint to this study, the deterioration of the EDSS of ≥1 point (baseline EDSS ≤ 5) or 0.5 points (baseline EDSS ≥5.5) must be confirmed after 6 months.
This is called 6-month confirmed progression (6M-CDPEDSS).
EDSS values to confirm progression must not be determined during an attack.
The maximum duration of an attack is limited to 90 days
|
month 36
|
Proportion of patients with six month confirmed disease progression by symbol digit modalities test (SDMT)
Time Frame: Up to 36 months
|
The SDMT is a sensitive and specific test for examining attention, concentration and information processing speed, which are typically impaired in cognitively impaired MS patients. The patients receive an SDMT test sheet. At the beginning of this sheet there are 9 numbers paired with 9 associated individual symbols. Below that are further lines with symbols and empty boxes. The patients must now verbally assign the correct numbers to the symbols as quickly as possible. Exercise examples are given at the beginning of the test which are not taken into account when evaluating the test. The number of correctly assigned items within 90 seconds results into the test score. The total duration of the test is about 5 minutes. SDMT: ≥4.0-point confirmed worsening from baseline score sustained for at least 6 months respectively |
Up to 36 months
|
Treatment effect of Siponimod on walking speed as measured by the timed 25 foot walk test (T25FWT)
Time Frame: Baseline, up to 36 months
|
The T25-FW is an objective and quantitative test of the lower extremities (Motl et al., 2017).
This stops the time in seconds that a patient needs to walk 25 feet (7.62 m).
The patient should walk as quickly and safely as possible.
This test is carried out twice in succession and the mean value of the time required is documented in seconds.
An improvement or deterioration of 20% is seen as a clinical meaningful change (Motl et al., 2017).
|
Baseline, up to 36 months
|
Treatment effect of Siponimod on quality of life based on EQ-5D
Time Frame: Baseline, month 36
|
The EQ-5D patient questionnaire is a generic multidimensional measuring instrument for describing health-related quality of life (EuroQol, 1999).
The five domains mobility, ability to take care of oneself, everyday activities, pain / discomfort and anxiety / depression are considered.
For the individual dimensions, the most appropriate answer from three given options is selected (1 = no problem, 2 = moderate problem, 3 = major problem).
In addition, the patient marks the current state of health on a scale from 0 (worst-conceivable state of health) to 100 (best-conceivable state of health).
|
Baseline, month 36
|
Treatment effect of Siponimod on fatigue measured by Fatigue Scale for Motor and Cognitive Functions (FSMC)
Time Frame: Baseline, month 36
|
The FSMC is a patient questionnaire to clarify cognitive and motor fatigue, a typical symptom of MS (Penner et al., 2009). With the help of the FSMC, a cognitive, a motor, and a total score are determined. Increased scores indicate higher impairment caused by fatigue. A 5-point scale (ranging from 'does not apply at all' to 'applies completely') produces a score between 1 and 5 for each scored question. |
Baseline, month 36
|
Treatment effect of Siponimod on fatigue measured by Beck's depression inventory (BDI)
Time Frame: Baseline, month 36
|
BDI is a patient questionnaire for measuring the severity of depression (Beck, 1972). Depression is a common symptom in MS and can cause fatigue. With the BDI test we assess the frequency of depression and its correlation to fatigue. This results in a scale from 0 to 63. The level of depression is evaluated according to the table below:
|
Baseline, month 36
|
Treatment effect of Siponimod on fatigue measured by Epworth sleepiness scale (ESS) questionnaire
Time Frame: Baseline, month 36
|
ESS is a patient questionnaire to measure daytime sleepiness (Ibanez et al, 2017). Results of the ESS will allow to correlate whether observed fatigue might be attributed to daytime sleepiness. The level of sleepiness is evaluated according to the table below: 0-5 Lower Normal Daytime Sleepiness 6-10 Higher Normal Daytime Sleepiness 11-12 Mild Excessive Daytime Sleepiness 13-15 Moderate Excessive Daytime Sleepiness 16-24 Severe Excessive Daytime Sleepiness |
Baseline, month 36
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceiticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Neoplasms
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Disease Attributes
- Neoplastic Processes
- Chronic Disease
- Multiple Sclerosis
- Multiple Sclerosis, Chronic Progressive
- Sclerosis
- Neoplasm Metastasis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Immunosuppressive Agents
- Immunologic Factors
- Sphingosine 1 Phosphate Receptor Modulators
- Siponimod
Other Study ID Numbers
- CBAF312ACH01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
-
State University of New York at BuffaloCompletedSecondary-progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsActive, not recruitingRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
University of UtahCompletedMultiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Secondary Progressive Multiple SclerosisUnited States
-
Tehran University of Medical SciencesCompletedMultiple Sclerosis | Mesenchymal Stem Cells | Secondary-Progressive Multiple SclerosisIran, Islamic Republic of
-
Novartis PharmaceuticalsActive, not recruitingActive Secondary Progressive Multiple SclerosisItaly
-
Stem Cell Medicine Ltd.WithdrawnSecondary Progressive Multiple Sclerosis (SPMS)Israel
-
Novartis PharmaceuticalsCompletedSecondary Progressive Multiple Sclerosis (SPMS)Japan
-
SanofiRecruitingRelapsing Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisBelgium
-
Casa Sollievo della Sofferenza IRCCSNeurocenter of Southern Switzerland; Associazione Revert ONLUS; Fondazione Cellule...CompletedSecondary-progressive Multiple SclerosisItaly, Switzerland
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
Clinical Trials on Siponimod
-
Novartis PharmaceuticalsCompletedRelapsing Remitting Multiple SclerosisHungary, Turkey, Spain, Germany, Canada, Switzerland, United States, Norway, Russian Federation, Italy, Finland, Poland
-
Novartis PharmaceuticalsActive, not recruitingActive Secondary Progressive Multiple SclerosisItaly
-
Novartis PharmaceuticalsRecruitingMultiple Sclerosis (MS)United States, Belgium, Taiwan, Italy, Germany, Canada, Estonia, Mexico, Croatia, Slovakia, Turkey, India, Spain, Argentina, France, Israel, Australia, Austria, Serbia, Brazil, Guatemala, Latvia, Poland, Portugal, Russian Federation, Romania and more
-
Novartis PharmaceuticalsRecruitingMultiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedSecondary Progressive Multiple Sclerosis (SPMS)Japan
-
Novartis PharmaceuticalsTerminatedActive DermatomyositisUnited States, Czechia, Japan
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisPoland, Hungary, Turkey, Spain, Germany, United States, Canada, Switzerland, Russian Federation, Norway, Italy, Finland
-
Novartis PharmaceuticalsTerminatedDermatomyositis | PolymyositisHungary, United States, Czechia, Sweden, United Kingdom
-
NovartisCompleted
-
Novartis PharmaceuticalsAvailable